SCHEMBL24316271

SCHEMBL24316271

O=C1Nc2cccc3c(C4(O)CCN(Cc5ccccc5)CC4)ccc1c23

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 2/20 0.48
POLB P06746 2/20 0.47
PARP1 P09874 2/20 0.44
CCR3 P51677 1/20 0.44
SIGMAR1 Q99720 2/20 0.42
DRD2 P14416 4/20 0.42
DRD4 P21917 3/20 0.42
DRD3 P35462 3/20 0.42
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
GAA P10253 1/20 0.40
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29611207 1.00 OPRL1 (0.48) OPRL1POLBPARP1CCR3SIGMAR1
SCHEMBL26597829 0.89 PARP1 (0.41) OPRL1POLBPARP1DRD2DRD4
SCHEMBL24316270 0.87 PARP1 (0.44) OPRL1POLBPARP1SIGMAR1DRD2
SCHEMBL24315780 0.80 PARP1 (0.41) POLBPARP1DRD2DRD4DRD3
SCHEMBL6042648 0.78 OPRL1 (0.56) OPRL1POLBCCR3SIGMAR1DRD2
SCHEMBL24315777 0.75 KDM4E (0.41) POLBPARP1KDM4EALDH1A1HTT
SCHEMBL6709096 0.75 OPRL1 (0.63) OPRL1POLBCCR3SIGMAR1DRD2
Hydrochloric Acid SCHEMBL26597822 0.74 KDM4E (0.40) POLBPARP1KDM4EALDH1A1HTT
SCHEMBL29611183 0.73 PARP1 (0.41) POLBPARP1DRD2DRD4DRD3
SCHEMBL24315947 0.73 PARP1 (0.41) POLBPARP1DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 OPRL1 2693/4885POLB 3232/4885PARP1 1566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.